Clinical Observation of Fuzheng Anzhong Decoction Combined with Capecitabine in the Treatment of Postoperative Patients with Triple-negative Breast Cancer of Qi-yin Deficiency Type
Objective To observe the therapeutic effect of Fuzheng Anzhong Decoction combined with capecitabine on postoperative patients with triple-negative breast cancer(TNBC)of qi-yin deficiency type. Methods A total of 60 TNBC postoperative patients with qi-yin deficiency type,who received treatment in Guangdong Second of Traditional Chinese Medicine Hospital from August 2022 to August 2023,were selected as the study objects and randomly divided into observation group and control group,with 30 cases in each group. The control group was treated with capecitabine,and the observation group was treated with Fuzheng Anzhong Decoction on the basis of treatment for the control group. The courses of treatment covered four weeks. The changes of traditional Chinese medicine(TCM)syndrome scores,serum levels of tumor markers,white blood cell(WBC)count,platelet(PLT)count and hemoglobin(HGB)level of the two groups were observed. The clinical efficacy and safety of the two groups were evaluated. Results (1) After treatment,the TCM syndrome score of the observation group was significantly lower than that before treatment (P<0.05),while the TCM syndrome score of the control group showed a decreasing trend,but the difference was not statistically significant(P>0.05). The TCM syndrome score of the observation group was significantly lower than that of the control group by the comparison between two groups after treatment (P<0.05). (2) After treatment,the levels of serum tumor markers,namely carcinoembryonic antigen (CEA),glycoprotein 125 (CA125),and glycoprotein 153 (CA153) in both groups were significantly lower than those before treatment (P<0.05),and the levels of CEA,CA125,and CA153 in the observation group were significantly lower than those in the control group (P<0.05).(3)After treatment,the levels of WBC,HGB,and PLT in the control group were significantly decreased compared with those before treatment (P<0.05),whereas the levels of WBC,HGB,and PLT in the observation group demonstrated a downward tendency,but without statistical significance(P>0.05). After treatment,the levels of WBC,HGB,and PLT in the observation group were higher than those in the control group by the comparison between two groups after treatment (P<0.05). (4) The total effective rate of 90.00％ (27/30) in the observation group was significantly higher than that of 33.33％(10/30) in the control group(P<0.05). The incidence of adverse reactions in observation group (16.67％) was significantly lower than that in control group (43.33％)(P<0.05). Conclusion Fuzheng Anzhong Decoction in combination with capecitabine can enhance the clinical efficacy of postoperative TNBC patients with qi-yin deficiency type,effectively alleviate the clinical symptoms of patients,lower the level of tumor markers,reduce the toxic and side effects of chemotherapy drugs,and exhibit high safety.
triple-negative breast cancerdeficiency of qi and yinFuzheng Anzhong Decoctioncapecitabinechemotherapytumor markersprognosis
万方数据
维普
